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BCR = B-cell receptor; PI3-K = phosphatidylinositol 3-kinase; PLC = phospholipase C.
Available online http://breast-cancer-research.com/content/3/1/005
Introduction
Syk is ubiquitously expressed in hematopoietic cells and
has been extensively studied as an effector of B cell recep-
tor (BCR) signaling [3]. BCR engagement induces signal-
ing cascades mediated by three families of nonreceptor
tyrosine kinases [3]: the ZAP-70 family (ZAP-70, Syk), the
Src family (Lyn, Fyn, Blk), and the Tec family (Btk, Itk, Etk).
After BCR activation, Syk-dependent signaling pathways
regulate the clonal expansion, differentiation, or apoptosis
of B cells. Phospholipase C (PLC)-g2 and phosphatidyli-
nositol 3-kinase (PI3-K) are key targets of Syk tyrosine
phosphorylation after BCR cross-linking [3]. In B cells, Syk
phosphorylation of PLC-g2 results in downstream activation
of the ERK and JNK kinases [4], whereas PI3-K phosphory-
lation by Syk mediates Akt activity [5]. Syk also preferen-
tially phosphorylates the a-tubulin subunits of microtubules,
which has been proposed to regulate the ability of the
microtubule cytoskeleton to function as a scaffold for the
assembly of signaling complexes [6].
In addition to breast epithelial cells, Syk expression has
also been observed in other nonhematopoietic cells. For
example, Syk is expressed in human hepatocytes, and use
of the Syk-selective inhibitor, piceatannol, indicated that
Syk is necessary for mitogen-activated protein kinase acti-
vation by G-protein coupled receptors in this cell type [7].
In human colon carcinoma cells, Syk gene expression is
repressed in a p53-dependent manner, suggesting that
loss of p53 function during tumorigenesis can lead to
deregulated Syk activity [8].
Characterization of murine Syk revealed that Syk is
expressed at high levels in normal mammary glands [9]. In
agreement with this latter study, recent findings of
Coopman  et al [2] showed that Syk is a potent modulator
of breast epithelial cell growth. Coopman et al initially
examined Syk mRNA and protein expression in a panel of
well-characterized breast cancer cell lines, normal
mammary gland tissue, and a normal breast epithelial cell
Commentary
Syk: a new player in the field of breast cancer
Zoe A Stewart and Jennifer A Pietenpol
Department of Biochemistry, Center in Molecular Toxicology, and the Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine,
Nashville, Tennessee, USA
Correspondence: Jennifer A Pietenpol, Department of Biochemistry, Center in Molecular Toxicology, Vanderbilt University School of Medicine,
Nashville, TN 37232, USA
Abstract
Breast tumor development and progression are thought to occur through a complex, multistep
process, including oncogene activation (eg HER2/neu) and mutation or loss of tumor suppressor
genes (eg p53). Determining the function of genetic alterations in breast carcinoma tumorigenesis and
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unexpected, since Syk function has been predominantly linked to hematopoietic cell signaling, and is
discussed further in this commentary.
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line [2]. Syk expression was readily detectable in normal
mammary tissue and epithelium, and in the noninvasive
breast carcinoma cell lines; however, Syk expression was
reduced or absent in the invasive breast tumor cell lines.
Of note, the Syk protein expressed in the noninvasive
breast tumor cells was catalytically active, because Syk
isolated from these cells was autophosphorylated in in
vitro kinase assays. In situ hybridization of normal and
pathologic human breast tissue samples verified Syk
expression in normal breast epithelium, whereas Syk
expression was reduced in in situ carcinomas and was
absent in invasive breast carcinomas.
Role of Syk in tumorigenesis
In order to elucidate the role of Syk in tumorigenicity,
Coopman et al [2] also analyzed Syk in mouse xenograft
tumor models. In one set of experiments, a Syk-negative
breast cancer cell line was stably transfected with wild-
type Syk or vector control, and pooled clones of each were
injected into the mammary fat pads of athymic nude mice.
Tumors that formed from the Syk-negative vector control
cells had a nearly fivefold greater mean tumor volume than
did tumors generated by cells that expressed Syk. Further-
more, these engineered cell lines were also tested for their
ability to form lung metastases after injection into the tail
veins of mice. Injection of Syk-transfected cells resulted in
the formation of a single metastatic colony in one of five
animals. In contrast, all animals that received vector
control-transfected cells had multiple metastatic lung
colonies. Additionally, the Syk-expressing cells had a signif-
icantly impaired ability to grow in anchorage-independent
conditions and to form invasive colonies in matrigel as
compared with vector control-transfected cells. In a parallel
set of experiments, a Syk-positive breast cell line was
stably transfected with a dominant-negative kinase-defi-
cient Syk or empty vector, and pooled clones of each were
injected into the mammary fat pads of athymic nude mice.
The kinase-deficient Syk-transfected cells had significantly
enhanced tumor potency and tumor growth as compared
with the vector control-transfected cells. However, expres-
sion of the kinase-deficient Syk was not sufficient to inhibit
invasive outgrowth in matrigel. Taken together, the data
from these tumor studies suggest that Syk can suppress
tumor growth and metastasis in breast cells in vivo.
Preliminary studies by Coopman et al [2], exploring Syk
mechanism of action in breast cells, failed to reveal signifi-
cant differences in the rates of apoptosis in Syk-express-
ing cells and Syk-deficient cells. Cells from Syk-containing
tumors were enlarged and had multilobed or multiple
nuclei. Furthermore, abnormal mitotic spindles were
detected in Syk-positive cells, suggesting that Syk may
inhibit tumor growth in breast cells by regulation of micro-
tubules. Interestingly, both Syk kinase activity and intact
Syk SH2 sites were necessary to suppress the invasive
outgrowth of cells in matrigel. However, mutation of the
autophosphorylation site (Y348F) in the Syk linker region
did not impair the ability of Syk to suppress invasive
growth. Because autophosphorylation of the Syk linker
region is required for the interaction of Syk with Vav1 and
PLC-g1 [10], this latter finding suggests that other Syk
effectors mediate Syk-dependent inhibition of invasive
growth in breast epithelial cells.
The findings by Coopman et al support a role for Syk func-
tion in breast tumor development and metastasis, and
raise many interesting questions as to potential Syk-effec-
tor pathways in breast epithelial cells, as well as the role of
other nonreceptor tyrosine kinases in breast cell signaling
cascades. In B cells, Syk activity is a key regulator of Akt
kinase activity after BCR engagement, because Syk
induces PI3-K-dependent Akt activation and thus inhibition
of apoptosis [5]. Because numerous studies have demon-
strated deregulated Akt activity in breast cancer cells [11],
it is tempting to speculate that Syk may also regulate Akt
activity in breast cells. However, only signaling pathways
that generate elevated Akt activity have been identified in
breast tumor cells. For example, PTEN is a negative regu-
lator of Akt activity and mutation in PTEN leads to
increased Akt activity and increased mammary tumors in
mice [12], whereas overexpression of HER2 results in
increased Akt activity in human breast tumor cells [13].
However, if Syk expression is reduced during human
breast cancer progression, then it is unlikely that Syk-
dependent signaling contributes to the increased Akt
activity observed in breast tumor cells.
Expression of the Syk-related ZAP-70 kinase was not
detected in any of the breast cancer cell lines examined by
Coopman et al. However, the role of other nonreceptor
tyrosine kinases in breast epithelial cell signaling remains
to be determined. Lyn, a member of the Src family of non-
receptor tyrosine kinases, opposes Syk function for Akt
activation in B lymphocytes, because Lyn-dependent sig-
naling reduces Akt activity [14]. Although Lyn expression
has been observed in a noninvasive breast cancer cell line,
a rigorous examination of Lyn expression during breast
cancer progression has not been performed [15]. If Lyn
expression is reduced concurrent with Syk expression
during breast cancer development, the loss of Lyn-depen-
dent inhibition may be one contributor to the elevated Akt
activity observed during tumorigenesis.
Several other lines of evidence support a role for Syk-
dependent signaling in breast tumorigenesis. First, allelic
loss of the human Syk locus on chromosome 9q22 has
been linked to lymph node metastasis of primary breast
cancer [16]. Furthermore, knockout of the negative Syk reg-
ulator c-Cbl in mice leads to development of mammary
epithelial hyperplasia [17]. Given the results of Coopman et
al, it will be interesting to evaluate Syk activity and micro-
tubule structures in c-Cbl-deficient mammary epithelial cells.c
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In contrast to what was observed by Coopman et al in
human breast samples, examination of Syk expression in
murine breast biopsies demonstrated that aggressive,
metastasizing mammary gland tumors had upregulated
Syk expression as compared with well differentiated, non-
metastasizing tumors [9]. However, tumor epithelial cells
were not separated from coassociated lymph node tissues
by laser capture microdissection in this latter study. Addi-
tionally, Syk activity was not directly examined in the
mammary gland tumors, and thus it is unclear whether the
Syk protein retained wild-type function. Alternatively, it is
possible that the murine tumors contained mutations in the
downstream effector(s) responsible for Syk-dependent
growth inhibition and metastasis in human breast epithelial
cells. Clearly, further in vivo experimentation using iso-
genic murine mammary cell models is necessary before
definitive conclusions can be made regarding the role of
Syk in murine mammary epithelial cell tumorigenesis.
Conclusion
The recent identification of Syk as a potent modulator of
breast epithelial cell growth has generated a need for
further exploration of the role of nonreceptor tyrosine
kinases in breast cancer progression and metastasis.
These initial results offer the promise that novel molecular
targets may be identified both for the prevention of breast
cancer development and for inhibition of metastatic breast
cancer spread. The continual elucidation of novel targets
such as Syk is a critical part of the endeavor to eradicate
breast cancer.
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